Αρχική World News Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with... World News Taletrectinib Demonstrates Durable Long-Term Efficacy in Both TKI-naïve and Crizotinib-pretreated Patients with Advanced ROS1-positive NSCLC Από Ogkologos - 7 Μαΐου, 2026 315 0 Facebook Twitter Google+ Pinterest WhatsApp Updated efficacy and safety results from the TRUST-I study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ EMA recommends granting a marketing authorisation for daraxonrasib Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? MOST POPULAR Is there a future without Pap testing? 21 Οκτωβρίου, 2020 Efficacy of Romiplostim In the Treatment and Prevention of Recurrence of... 26 Μαρτίου, 2026 3-Year-Old Boy Receives Hundreds Of Sweet Birthday Cards In The Mail... 26 Ιουνίου, 2019 What can elephants teach us about cancer? 12 Αυγούστου, 2023 Φόρτωση περισσοτέρων HOT NEWS DeFi Trial: Smart Design and Impressive Results For the Benefit of... Study Explores Jaw Problem Linked to Zoledronic Acid, Finds Risk Factors EMA Adopts a Positive Opinion for a New Indication for Pembrolizumab Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with...